Searching for source:EMA

31,109 results
Record publications over time
Ironsift results are limited for unregistered users. Register or log in to see all records.

EU Clinical Trial 2005-001698-89 – EMA – Jun 8, 2006

Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen

Main objective of the trial: To perform prospective analysis of (i) gene expression profiles; (ii) previously identified candidate genes; and (iii) blood analysis, before, during, and after neoadjuvant therapy with exemestane or tamoxifen to identify...
Full record

EU Clinical Trial 2011-006324-20 – EMA – Nov 29, 2012

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Metformin compared to Therapy with Placebo added to Saxagliptin in Combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Saxagliptin + Pharmacogenetics Blood Sample Amendment 01 - Site Specific, (V1.0, dated 22-June-2012) Revised protocol 01 incorporating amendment 02

Main objective of the trial: The purpose of this study is to learn if BMS-512148 (dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a...
Full record

EU Clinical Trial 2012-001984-66 – EMA – Apr 25, 2013

A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimumab and MTX

Main objective of the trial: To demonstrate the treatment effect of sarilumab and methotrexate (MTX) compared to etanercept and methotrexate (MTX) in patients with rheumatoid arthritis (RA) and an inadequate response to adalimumab and methotrexate by...
Full record

EU Clinical Trial 2005-000407-34 – EMA – Aug 12, 2005

A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

Main objective of the trial: After 24 weeks: (1) To assess the effect of co-administration of MK-0431 and metformin compared with the effect of metformin monotherapy on HbA1c; (2) To assess the effect of co-administration of MK-0431 and metformin com...
Full record

EU Clinical Trial 2009-017999-25 – EMA – Nov 12, 2010

An Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to < 6 Years with Chronic Kidney Disease Receiving Dialysis

Main objective of the trial: • To evaluate the safety and tolerability of cinacalcet HCl after single administration to pediatric patients aged 28 days to < 6 years with CKD receiving dialysis
Full record

EU Clinical Trial 2007-003780-50 – EMA – Jul 30, 2008

Estudio de fase 3, abierto y aleatorizado, de bosutinib comparado con imatinib en sujetos con leucemia mieloide crónica cromosoma Filadelfia positiva en fase crónica, de diagnóstico reciente A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Main objective of the trial: Compare the rate of complete cytogenetic response (CCyR) at one year in chronic phase subjects receiving bosutinib alone versus chronic phase subjects receiving imatinib alone.
Full record

EU Clinical Trial 2010-021870-12 – EMA – Feb 15, 2011

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer

Main objective of the trial: The primary objective of this study is to confirm the effect of tasquinimod on delaying disease progression or death compared with placebo.
Full record

EU Clinical Trial 2009-015507-52 – EMA – Nov 13, 2009

A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.

Main objective of the trial: To compare progression-free survival (PFS), in patients treated with PAN in combination with BTZ/Dex vs. patients treated with placebo in combination with BTZ/Dex.
Full record

EU Clinical Trial 2006-006417-32 – EMA – Feb 6, 2008

Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4)

Main objective of the trial: To confirm the hypothesis that vicriviroc 30 mg QD provides added benefit in plasma HIV-1 RNA reduction when added to optimized background therapy (OBT), as measured by the proportion of subjects with HIV RNA <50 copies/m...
Full record

EU Clinical Trial 2012-000327-40 – EMA – May 27, 2013

A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction

Main objective of the trial: (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in subjects with HF and left ventricular systolic dysfunction and (ii) to characterize its pharma...
Full record

EU Clinical Trial 2008-005942-22 – EMA – Jan 15, 2009

A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations

Main objective of the trial: To determine the efficacy of deforolimus in patients with KRAS mutant NSCLC who have progressed after two prior chemotherapy regimens compared to placebo by progression free survival analysis of randomized patients who ha...
Full record
Register to view full records and receive email notifications.

EU Clinical Trial 2004-003927-11 – EMA – Aug 4, 2005

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or ValproicAcid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode

Main objective of the trial: The primary objective of this trial is to demonstrate clinical and statistical superiority of asenapine compared to placebo in subjects who have not completely responded to continuing treatment with lithium or VPA to trea...
Full record

EU Clinical Trial 2011-003574-84 – EMA – Jan 31, 2012

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC).

Main objective of the trial: To evaluate efficacy of GC33 vs. placebo through investigator-assessed progression-free survival (PFS) in patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) previously treated with at least 1...
Full record

EU Clinical Trial 2012-002847-28 – EMA – Apr 11, 2013

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer’s Disease

Main objective of the trial: 1. To demonstrate the clinical efficacy of leuco-methylthioninium bis(hydromethanesulfonate) (also known as LMTM, TRx0237) in mild Alzheimer's disease based on change from baseline on the following coprimary endpoints: •...
Full record

EU Clinical Trial 2008-004760-39 – EMA – Apr 3, 2009

A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribavirin

Main objective of the trial: The primary objective of this study is to compare the efficacy of boceprevir 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2a (PEG2a) 180 mcg weekly (QW) subcutaneously (SC) plus ribavi...
Full record

EU Clinical Trial 2007-000343-10 – EMA – Nov 20, 2007

Ensayo Clínico en Fase IV para evaluar la Seguridad y Tolerabilidad del ZOSTAVAX™ en pacientes ≥ a 60 años A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age

Main objective of the trial: El objetivo del estudio consiste en evaluar la seguridad general de ZOSTAVAX™ en pacientes ≥ a 60 años.
Full record

EU Clinical Trial 2007-000037-19 – EMA – Jul 15, 2008

A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in Patients With Mixed Hyperlipidemia

Main objective of the trial: Main objective: In patients with mixed hyperlipidemia, to evaluate the effect of MK 0524B (dosed as MK-0524A coadministered with simvastatin) compared to atorvastatin in the percent reduction from baseline in the LDL-C/HD...
Full record

EU Clinical Trial 2013-003314-41 – EMA – Aug 5, 2014

A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

Main objective of the trial: - To evaluate the overall response rate (ORR) following treatment with idelalisib (IDELA) plus rituximab in subjects with previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion.
Full record

EU Clinical Trial 2011-004168-30 – EMA – Aug 7, 2012

A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma

Main objective of the trial: To show that progression-free survival in the pazopanib group is not inferior to that in the doxorubicin group
Full record

EU Clinical Trial 2015-002752-27 – EMA – Apr 4, 2018

Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match - N²M² (NOA-20)

Main objective of the trial: Phase I: Determination of safety and tolerability of the systemic molecularly defined therapy in conjunction with radiotherapy. The aim is to proof the proposed optimal monocompound dose also in conjunction with radiother...
Full record

EU Clinical Trial 2012-000218-12 – EMA – Sep 17, 2013

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ?6 to < 72 Months of Age

Main objective of the trial: The relative efficacy of aQIV compared to comparator vaccine as determined by RT-PCR-confirmed influenza La eficacia relativa de aQIV en comparación con un comparador según venga por RT-PCR de gripe .
Full record
Register to view full records and advanced analytics.

EU Clinical Trial 2015-001200-55 – EMA – Sep 23, 2015

A single postoperative bisphosphonate infusion to improve patient reported function after hip or knee replacement.

Main objective of the trial: The ultimate purpose of the study is to investigate if postoperative bisphosphonate treatment can reduce the risk of late prosthetic loosening in patients operated with primary hip- and knee arthroplasty due to osteoarthr...
Full record

EU Clinical Trial 2004-004252-40 – EMA – Sep 5, 2005

An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer

Main objective of the trial: To determine the activity of EPO906 administered once every 3 weeks to patients with advanced NSCLC
Full record

EU Clinical Trial 2013-002737-38 – EMA – May 13, 2014

A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations

Main objective of the trial: To evaluate efficacy of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 fusion genes (primary endpoint: objective response rate (ORR) according to RECIST v.1.1)
Full record

EU Clinical Trial 2013-003905-24 – EMA – Feb 12, 2014

ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RCC

Main objective of the trial: To demonstrate an improvement in disease free survival (DFS) in patients at high risk of recurrent RCC randomly assigned to adjuvant axitinib (Arm A) vs. Placebo (Arm B) after nephrectomy. Demostrar una mejora en la super...
Full record

EU Clinical Trial 2017-004148-39 – EMA – Jan 1, 2017

An open-label, first-in-human, dose escalation study of SAR440234 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), or high risk myelodysplasia (HR-MDS)

Main objective of the trial: - Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in patients with R/R AML (relapsed or refractory acute myeloid leukemia), HR-MDS (high risk myelodysplastic synd...
Full record

EU Clinical Trial 2016-002005-19 – EMA – Aug 19, 2016

RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE

Main objective of the trial: To evaluate the efficacy of azeliragon on cognitive [Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)] and global function [Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)] measures in patients with...
Full record

EU Clinical Trial 2010-019000-22 – EMA – Nov 29, 2010

Long-Term Eslicarbazepine Acetate Extension Study

Main objective of the trial: To evaluate the 1-year and post-1-year safety and tolerability of eslicarbazepine acetate flexible dosing within the range of 800 mg to 2400 mg in subjects with partial epilepsy who have participated in an 18-week double-...
Full record

EU Clinical Trial 2013-003134-33 – EMA – Jan 31, 2014

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA

Main objective of the trial: The primary objective of the study is to evaluate the effect of multiple doses of REGN1033 administered SC for 12 weeks on total lean body mass measured by DEXA in patients with sarcopenia. El objetivo principal del estud...
Full record

EU Clinical Trial 2016-004687-19 – EMA – Apr 23, 2018

A randomized controlled trial evaluating the additional effect of topical coal tar to a topical corticosteroid regimen in patients aged >16 years of age with moderate-severe atopic dermatitis.

Main objective of the trial: To evaluate the additional effect of coal tar treatment to a corticosteroid regimen in adults (aged >16 years of age) with moderate to severe atopic dermatitis, based on the percentage change in Eczema Area and Severity I...
Full record

EU Clinical Trial 2015-002397-21 – EMA – Nov 30, 2015

FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIL

Main objective of the trial: To demonstrate the safety of enalapril Orodispersible Minitablets (ODMTs).
Full record
Register to view full records and use our APIs.

EU Clinical Trial 2015-002335-17 – EMA – Nov 30, 2015

ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN CHILDREN WITH HEART FAILURE DUE TO DILATED CARDIOMYOPATHY

Main objective of the trial: To obtain paediatric pharmacokinetic data of enalapril and its active metabolite enalaprilat in paediatric patients treated with enalapril ODMTs to describe the dose exposure in the paediatric population with DCM.
Full record

EU Clinical Trial 2012-005054-30 – EMA – Apr 8, 2013

Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of lower limb spasticity in children and adolescents (age 2 - 17 years) with cerebral palsy

Main objective of the trial: The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) are effective in treating children/adolescents (age 2-17 years) with increased muscle tension/uncontrollabl...
Full record

EU Clinical Trial 2018-000811-26 – EMA – Sep 19, 2018

A phase III, multicentric, Randomized, open-label, parallel-group clinical trial to detect false positives from first-trimester preeclampsia screening (StopPRE) at the second-trimester of pregnancy.

Main objective of the trial: To demostrate no increasement of incidence of pre-emclampsia, comparing with a control-group patients who are taking the treatment as usual, when sFlt-1/PlGF ratio is less than 38 and patients are under 24-27 weeks of pre...
Full record

EU Clinical Trial 2018-001201-93 – EMA – Sep 19, 2018

Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma

Main objective of the trial: To evaluate the effectiveness of preoperative treatment with cabozantinib (Cabometyx), measured by the radiological response rate prior to cytoreductive nephrectomy, in patients with advanced or metastatic renal cell carc...
Full record

EU Clinical Trial 2017-000992-10 – EMA – Jun 28, 2017

Prednisolone treatment in acute interstitial nephritis

Main objective of the trial: To investigate the effect of prednisolone treatment in acute interstitial nephritis. Patienter med akut interstitiel nefritis (AIN) debuterer med akut nyresvigt. Der kan være flere ledsagende symptomer. Tilstanden giver r...
Full record

EU Clinical Trial 2006-006088-22 – EMA – Mar 28, 2011

Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinomatosis of gastric cancer incl. adenocarcinoma of the esophagogastreal junction

Main objective of the trial: Evaluation of the efficacy of hyperthermic intraoperative chemotherapy (HIPEC) (extension of survival starting at randomisation) by combination of pre-and postoperative chemotherapy + cytoreductive surgery and HIPEC compa...
Full record

EU Clinical Trial 2018-002822-22 – EMA – Sep 21, 2018

US-guided Percutaneous needle tenotomy in Patients with Lateral Elbow Tendinopathy: A multicenter Randomized Controlled Trial

Main objective of the trial: To study the effect of Percutaneous Needle Tenotomy (PNT) and structured exercise on function and pain of patients with Lateral Elbow Tendinopathy (LET). Het effect van Percutane Naald Tenotomie (PNT) en gestructureerde o...
Full record

EU Clinical Trial 2015-005761-23 – EMA – Sep 26, 2016

A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cyclo (HP-β-CD) in patients with Niemann-Pick disease type C (NPC-1) and the pharmacodynamic effects of treatment upon markers of cholesterol metabolism and clinical outcomes

Main objective of the trial: Stage 1 • To compare the plasma pharmacokinetics of hydroxypropyl-β-cyclodextrin following 3 different single doses of intravenous Trappsol Cyclo in patients with NPC-1 Stage 2 • To evaluate the efficacy and tolerability...
Full record

EU Clinical Trial 2015-003953-16 – EMA – Apr 5, 2016

A Phase IIIb study of the efficacy of dexamethasone in irreversible hearing loss prevention in subjects with Ototoxic Oncological Treatment. Otoprotection in cancer treatment.

Main objective of the trial: Investigate the potential protective effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in patients with malignan neoplasm, through pure tone audiometry and Video Heald Impulse Test. Det...
Full record

EU Clinical Trial 2016-004008-71 – EMA – Jan 19, 2017

The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’

Main objective of the trial: To determine the influence of curcumin with or without piperine, in patients with estrogen receptor positive breast cancer, on tamoxifen/endoxifen plasma pharmacokinetics (AUC). De invloed van kurkuma met of zonder piperi...
Full record
Register to view full records and disable ads.

EU Clinical Trial 2016-005244-42 – EMA – Jun 4, 2018

An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone.

Main objective of the trial: Subjects with salvageable giant cell rich tumors: - To evaluate subjects who do not require surgery during the study - To evaluate subjects who are able to undergo a less morbid surgical procedure compared with the planne...
Full record

EU Clinical Trial 2017-004616-19 – EMA – Sep 12, 2018

A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic rhinoconjunctivitis patients.

Main objective of the trial: The primary objective of this study is to determine in patients with moderate to severe grass pollen allergic rhinoconjunctivitis (ARC) the concentrations of grass pollen allergen at which cumulatively 50% +/- 10% of pati...
Full record

EU Clinical Trial 2014-002941-23 – EMA – Sep 30, 2015

A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndrome in children and adults

Main objective of the trial: To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in patients with LGS. Drop seizure is defined as an attack or spell (atonic, tonic, or ton...
Full record

EU Clinical Trial 2014-002665-30 – EMA – Jan 11, 2016

Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of AIO/CAO-V/CAOGI

Main objective of the trial: Overall survival (OS) (The duration of OS will be determined by measuring the time interval from randomization to the date of death or last observation (censored))
Full record

EU Clinical Trial 2014-004878-42 – EMA – Feb 25, 2015

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schizophrenia, Followed by a 24-Week, Open-Label Extension.

Main objective of the trial: To evaluate the efficacy of MIN-101 compared to placebo in improving the negative symptoms of schizophrenia as measured by the change from Baseline in the Positive and Negative Syndrome Scale (PANSS) negative subscale sco...
Full record

EU Clinical Trial 2015-004240-19 – EMA – Mar 2, 2016

A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway.

Main objective of the trial: To determine whether adjuvant treatment with 160 mg ASA once daily for 3 years can improve Time To Recurrence (TTR) in patients with colorectal cancer with somatic alterations in the PIK3CA (exon 9 and 20) compared with p...
Full record

EU Clinical Trial 2016-004906-32 – EMA – Dec 21, 2017

A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Severe Renal Impairment who have Inadequate Glycemic Control

Main objective of the trial: To demonstrate the superiority of sotagliflozin dose 1 versus placebo with respect to hemoglobin A1c (HbA1c) reduction in patients with Type 2 diabetes who have inadequate glycemic control and severe renal impairment A 40...
Full record

EU Clinical Trial 2012-000067-25 – EMA – Oct 19, 2012

Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia

Main objective of the trial: To treat children with ALL with the best available treatment as possible, based upon the risk factors of the patient at diagnosis. Behandeling van kinderen met ALL volgens de best beschikbare therapie, rekening houdend me...
Full record

EU Clinical Trial 2004-000815-25 – EMA – Mar 22, 2005

A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy.

Main objective of the trial: The primary objective of this study is to compare overall survival time following treatment with ALIMTA 500 mg/m2 versus ALIMTA 900 mg/m2 in patients with locally advanced or metastatic (Stage III or IV) NSCLC who have fa...
Full record